

# Yuh-Min Chen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7461283/publications.pdf>

Version: 2024-02-01

160  
papers

6,585  
citations

109321

35  
h-index

74163

75  
g-index

161  
all docs

161  
docs citations

161  
times ranked

7588  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mouth opening/breathing is common in sleep apnea and linked to more nocturnal water loss. <i>Biomedical Journal</i> , 2023, 46, 100536.	3.1	2
2	Sequence for Surgical Resection of Primary Lung Tumor for Oligometastatic Non-small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2022, 113, 1333-1340.	1.3	1
3	Risk of work-related injury in workers with obstructive sleep apnea: A systematic review and meta-analysis. <i>Journal of Sleep Research</i> , 2022, 31, e13446.	3.2	5
4	Consensus statement and recommendations on the treatment of COVID-19: 2021 update. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 5-17.	1.4	6
5	Disease Progression in Patients With Nontuberculous Mycobacterial Lung Disease of Nodular Bronchiectatic (NB) Pattern: The Roles of Cavitory NB and Soluble Programmed Death Protein-1. <i>Clinical Infectious Diseases</i> , 2022, 75, 239-247.	5.8	6
6	Oncogenic circRNA C190 Promotes Non-Small Cell Lung Cancer via Modulation of the EGFR/ERK Pathway. <i>Cancer Research</i> , 2022, 82, 75-89.	0.9	48
7	Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. <i>Clinical Cancer Research</i> , 2022, 28, 1117-1126.	7.0	52
8	PD-L1 Expression in Monocytes Correlates with Bacterial Burden and Treatment Outcomes in Active Pulmonary Tuberculosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1619.	4.1	5
9	Recent Advances in the Diagnosis and Management of Multiple Primary Lung Cancer. <i>Cancers</i> , 2022, 14, 242.	3.7	13
10	An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100292.	1.1	3
11	Reduced FEV1 as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors. <i>Frontiers in Medicine</i> , 2022, 9, 860733.	2.6	2
12	Application of Artificial Intelligence in Lung Cancer. <i>Cancers</i> , 2022, 14, 1370.	3.7	38
13	Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 409-413.	1.4	9
14	Circular RNA hsa_circ_0000190 Facilitates the Tumorigenesis and Immune Evasion by Upregulating the Expression of Soluble PD-L1 in Non-Small-Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 64.	4.1	19
15	Abstract CT572: Phase 1b dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd) in combination with durvalumab and cisplatin, carboplatin, or pemetrexed in advanced or metastatic, HER2-overexpressing, nonsquamous non-small cell lung cancer (NSCLC): DESTINY-Lung03. <i>Cancer Research</i> , 2022, 82, CT572-CT572.	0.9	1
16	Abstract CT504: A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRASG12C inhibitor, in patients with advanced or metastatic solid tumor harboring KRASG12C mutation. <i>Cancer Research</i> , 2022, 82, CT504-CT504.	0.9	2
17	Tepotinib in Asian patients with advanced NSCLC with <i>MET</i> exon 14 ( <i>MET</i> ex14) skipping. <i>Journal of Clinical Oncology</i> , 2022, 40, 9120-9120.	1.6	1
18	State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7037.	4.1	5

#	ARTICLE	IF	CITATIONS
19	Lung Cancer in Republic of China. <i>Journal of Thoracic Oncology</i> , 2021, 16, 519-527.	1.1	34
20	Sub-multiplicative interaction between polygenic risk score and household coal use in relation to lung adenocarcinoma among never-smoking women in Asia. <i>Environment International</i> , 2021, 147, 105975.	10.0	12
21	Role of Soluble T-Cell Immunoglobulin Mucin Domain-3 in Differentiating Nontuberculous Mycobacterial Lung Disease from Pulmonary Colonization. <i>Archivos De Bronconeumologia</i> , 2021, , .	0.8	5
22	Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis. <i>Targeted Oncology</i> , 2021, 16, 207-214.	3.6	9
23	Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations. <i>International Journal of Clinical Oncology</i> , 2021, 26, 841-850.	2.2	2
24	Statin use and impact on tuberculosis risk. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1093-1098.	4.4	7
25	<i>Mycobacterium tuberculosis</i> â€derived circulating cell-free DNA in patients with pulmonary tuberculosis and persons with latent tuberculosis infection. <i>PLoS ONE</i> , 2021, 16, e0253879.	2.5	18
26	Treatment patterns and survival in patients with small cell lung cancer in Taiwan. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 772-777.	1.4	3
27	Comparison of colistin-induced nephrotoxicity between two different formulations of colistin in critically ill patients: a retrospective cohort study. <i>Antimicrobial Resistance and Infection Control</i> , 2021, 10, 111.	4.1	6
28	Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer. <i>Scientific Reports</i> , 2021, 11, 16122.	3.3	13
29	Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	2.5	3
30	Programmed Death Ligand 2 Gene Polymorphisms Are Associated With Lung Adenocarcinoma Risk in Female Never-Smokers. <i>Frontiers in Oncology</i> , 2021, 11, 753788.	2.8	4
31	RNA Modifications and Epigenetics in Modulation of Lung Cancer and Pulmonary Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10592.	4.1	61
32	Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IBâ€III A non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet, The</i> , 2021, 398, 1344-1357.	13.7	689
33	Highlight of severe acute respiratory syndrome coronavirus-2 vaccine development against COVID-19 pandemic. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 9-13.	1.4	2
34	Clinical manifestation and disease progression in COVID-19 infection. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 3-8.	1.4	115
35	Chest film demonstrating reverse batwing pulmonary opacities in a patient with COVID-19 pneumonia. <i>Tuberculosis and Respiratory Diseases</i> , 2021, , .	1.8	1
36	The clinical manifestations and interval changes of reverse-transcriptase quantitative polymerase chain reactions among different specimens of coronavirus disease 2019 patients. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 151-157.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Predicting Lung Cancer Occurrence in Never-Smoking Females in Asia: TNSF-SQ, a Prediction Model. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 452-459.	2.5	31
38	Sâ€ plus cisplatin as firstâ€line treatment of patients with advanced nonâ€small cell lung cancer in Taiwan. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e68-e73.	1.1	1
39	Overview of coronavirus disease 2019: Treatment updates and advances. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 805-808.	1.4	10
40	Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI. <i>Targeted Oncology</i> , 2020, 15, 503-512.	3.6	12
41	Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer. <i>PLoS ONE</i> , 2020, 15, e0236503.	2.5	25
42	The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 14965.	3.3	21
43	Using lung ultrasound changes to evaluate the response of recruitment maneuver in a patient recovering from coronavirus disease 2019 with acute respiratory distress syndrome. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 1117-1120.	1.4	2
44	First-line combination immunotherapy for metastatic non-small cell lung cancer. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 433-441.	1.4	2
45	Nonâ€small cell lung cancer in the very young: Higher EGFR/ALK mutation proportion than the elder. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 461-465.	1.4	11
46	Impact of cooking oil fume exposure and fume extractor use on lung cancer risk in non-smoking Han Chinese women. <i>Scientific Reports</i> , 2020, 10, 6774.	3.3	41
47	Tepotinib in Nonâ€Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations. <i>New England Journal of Medicine</i> , 2020, 383, 931-943.	27.0	500
48	Masks and medical care: Two keys to Taiwan's success in preventing COVID-19 spread. <i>Travel Medicine and Infectious Disease</i> , 2020, 38, 101780.	3.0	30
49	Plasma Level of Circular RNA hsa_circ_0000190 Correlates with Tumor Progression and Poor Treatment Response in Advanced Lung Cancers. <i>Cancers</i> , 2020, 12, 1740.	3.7	45
50	Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1817-1826.	1.7	8
51	ASTRIS: a global real-world study of osimertinib in >3000 patients with <i>EGFR</i> T790M positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 3003-3014.	2.4	42
52	A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of 188Re-liposome in patients with metastatic tumors. <i>EJNMMI Research</i> , 2019, 9, 46.	2.5	17
53	Impact of Intermittent Hypoxia on Sepsis Outcomes in a Murine Model. <i>Scientific Reports</i> , 2019, 9, 12900.	3.3	2
54	5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 1098-1108.	10.7	88

#	ARTICLE	IF	CITATIONS
55	Prognostic factors and first-line treatment modalities in nonagenarian patients with lung cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 439-441.	1.0	1
56	Efficacy of Paclitaxel plus TS1 against previously treated EGFR mutated non-small cell lung cancer. <i>PeerJ</i> , 2019, 7, e7767.	2.0	1
57	The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1156-1169.	2.4	47
58	PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion. <i>Journal of Thoracic Oncology</i> , 2018, 13, 447-453.	1.1	38
59	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 521-536.	10.7	486
60	The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment. <i>Integrative Cancer Therapies</i> , 2017, 16, 126-131.	2.0	16
61	Comorbidities and risk of mortality in patients with sleep apnea. <i>Annals of Medicine</i> , 2017, 49, 377-383.	3.8	34
62	Sleep disorders and an increased risk of Parkinson's disease in individuals with non-apnea sleep disorders: a population-based cohort study. <i>Journal of Sleep Research</i> , 2017, 26, 623-628.	3.2	35
63	Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer – A multicenter retrospective SEQUENCE study. <i>Lung Cancer</i> , 2017, 104, 58-64.	2.0	22
64	Risk of Second Primary Malignancies in Lung Cancer Survivors – The Influence of Different Treatments. <i>Targeted Oncology</i> , 2017, 12, 219-227.	3.6	12
65	Brain metastasis features and association with tumor epidermal growth factor receptor mutation in patients with adenocarcinoma of the lung. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e440-e448.	1.1	7
66	Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 663-673.	5.6	24
67	Immune checkpoint inhibitors for nonsmall cell lung cancer treatment. <i>Journal of the Chinese Medical Association</i> , 2017, 80, 7-14.	1.4	39
68	Induced Pluripotent Stem Cell-conditioned Medium Suppressed Melanoma Tumorigenicity Through the Enhancement of Natural-Killer Cellular Immunity. <i>Journal of Immunotherapy</i> , 2016, 39, 153-159.	2.4	4
69	Erlotinib Salvage Therapy in Pulmonary Adenocarcinoma Patients With Disease Progression After Previous EGFR-TKI Treatment. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 556-562.	1.3	3
70	A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma. <i>Cancer Biomarkers</i> , 2016, 16, 19-29.	1.7	6
71	Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations. <i>Human Molecular Genetics</i> , 2016, 26, ddw414.	2.9	50
72	Spectrum of cancer risk among Taiwanese with chronic obstructive pulmonary disease. <i>International Journal of Clinical Oncology</i> , 2016, 21, 1014-1020.	2.2	17

#	ARTICLE	IF	CITATIONS
73	Fanconi anemia genes in lung adenocarcinoma- a pathway-wide study on cancer susceptibility. Journal of Biomedical Science, 2016, 23, 23.	7.0	16
74	Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. Human Molecular Genetics, 2016, 25, 620-629.	2.9	50
75	Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI). Journal of Chemotherapy, 2016, 28, 50-58.	1.5	9
76	Adjuvant Therapy for Thymic Carcinoma – A Decade of Experience in a Taiwan National Teaching Hospital. PLoS ONE, 2016, 11, e0146609.	2.5	7
77	Sleep Disorders and Increased Risk of Autoimmune Diseases in Individuals without Sleep Apnea. Sleep, 2015, 38, 581-586.	1.1	67
78	Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia. International Journal of Cancer, 2015, 137, 311-319.	5.1	72
79	A phase I multicenter study of aroquinolol in patients with metastatic non-small-cell lung cancer who have received at least two prior systemic treatment regimens, including one platinum-based chemotherapy regimen. Molecular and Clinical Oncology, 2015, 3, 1375-1380.	1.0	14
80	Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients. Oncologist, 2015, 20, 758-766.	3.7	9
81	The Association Between Tumor Epidermal Growth Factor Receptor (EGFR) Mutation and Multiple Primary Malignancies in Patients With Adenocarcinoma of the Lungs. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 147-151.	1.3	11
82	Amyloidosis and the risk of cancer: a nationwide population-based study. International Journal of Clinical Oncology, 2015, 20, 1244-1251.	2.2	2
83	Sleep Apnea and Risk of Panic Disorder. Annals of Family Medicine, 2015, 13, 325-330.	1.9	18
84	Maintenance therapy with gefitinib (G)/pemetrexed (P) versus P alone after induction therapy with P/platinum for metastatic lung adenocarcinoma (MLADC) harboring no sensitizing epidermal growth factor receptor mutation (sEGFRm): A phase II multicenter randomized open-label study (GENIUS trial).. Journal of Clinical Oncology, 2015, 33, 8043-8043.	1.6	0
85	Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance. Journal of Personalized Medicine, 2014, 4, 297-310.	2.5	16
86	Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung. Oncology Letters, 2014, 7, 2180-2184.	1.8	15
87	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
88	Interleukin-17A Modulates Circulating Tumor Cells in Tumor Draining Vein of Colorectal Cancers and Affects Metastases. Clinical Cancer Research, 2014, 20, 2885-2897.	7.0	49
89	Number of liver metastatic nodules affects treatment options for pulmonary adenocarcinoma patients with liver metastases. Lung Cancer, 2014, 86, 225-230.	2.0	10
90	Latent TB infection in newly diagnosed lung cancer patients – A multicenter prospective observational study. Lung Cancer, 2014, 85, 472-478.	2.0	23

#	ARTICLE	IF	CITATIONS
91	Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma. PLoS ONE, 2014, 9, e107160.	2.5	11
92	Recent advances in the development of mutant-selective EGFR inhibitors for non-small cell lung cancer patients with EGFR-TKI resistance. Translational Lung Cancer Research, 2014, 3, 368-9.	2.8	5
93	Epidermal growth factor receptor mutation in adenosquamous carcinoma: A step forward. Journal of the Chinese Medical Association, 2013, 76, 477-478.	1.4	1
94	Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer. Journal of the Chinese Medical Association, 2013, 76, 249-257.	1.4	42
95	The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer. Journal of the Chinese Medical Association, 2013, 76, 682-685.	1.4	8
96	Influence of chemotherapy on EGFR mutation status. Translational Lung Cancer Research, 2013, 2, 442-4.	2.8	9
97	Usage of EGFR-TKI and WBRT in NSCLC patients with brain metastases. Annals of Palliative Medicine, 2013, 2, 108-10.	1.2	5
98	Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations. Experimental and Therapeutic Medicine, 2012, 3, 207-213.	1.8	19
99	Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaïve, Advanced, Non-small Cell Lung Cancer Patients Aged 70 Years or Older. Journal of Thoracic Oncology, 2012, 7, 412-418.	1.1	61
100	Association between Tumor Epidermal Growth Factor Receptor Mutation and Pulmonary Tuberculosis in Patients with Adenocarcinoma of the Lungs. Journal of Thoracic Oncology, 2012, 7, 299-305.	1.1	52
101	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncology, The, 2012, 13, 528-538.	10.7	904
102	Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib. Oncology Letters, 2012, 3, 713-717.	1.8	13
103	A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II.. Journal of Clinical Oncology, 2012, 30, 7519-7519.	1.6	15
104	Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/ gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator's choice chemotherapy following progression on afatinib monotherapy.. Journal of Clinical Oncology, 2012, 30, 7557-7557.	1.6	14
105	Changing causes of death post-epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) era in patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, e18132-e18132.	1.6	0
106	Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status. Journal of the Chinese Medical Association, 2011, 74, 209-214.	1.4	16
107	First-line Systemic Therapy for Metastatic Non-small-cell Lung Cancer – A Review. Journal of Experimental and Clinical Medicine, 2011, 3, 116-120.	0.2	7
108	Different Efficacies of Erlotinib and Gefitinib in Taiwanese Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Multicenter Study. Journal of Thoracic Oncology, 2011, 6, 148-155.	1.1	26

#	ARTICLE	IF	CITATIONS
109	Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS). <i>Journal of Thoracic Oncology</i> , 2011, 6, 1872-1880.	1.1	132
110	A Phase II Randomized Trial of Gefitinib Alone or with Tegafur/Uracil Treatment in Patients with Pulmonary Adenocarcinoma Who had Failed Previous Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1110-1116.	1.1	28
111	<i>EGFR</i>L858R Mutation and Polymorphisms of Genes Related to Estrogen Biosynthesis and Metabolism in Never-Smoking Female Lung Adenocarcinoma Patients. <i>Clinical Cancer Research</i> , 2011, 17, 2149-2158.	7.0	28
112	Second-Line Therapy for Elderly Patients with Non-small Cell Lung Cancer Who Failed Previous Chemotherapy Is as Effective as for Younger Patients. <i>Journal of Thoracic Oncology</i> , 2010, 5, 376-379.	1.1	21
113	Interactive Effect of Cigarette Smoking With Human 8-Oxoguanine DNA N-Glycosylase 1 (hOGG1) Polymorphisms on the Risk of Lung Cancer: A Case-Control Study in Taiwan. <i>American Journal of Epidemiology</i> , 2009, 170, 695-702.	3.4	53
114	A Polymorphism in the <i>APE1</i> Gene Promoter is Associated with Lung Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 223-229.	2.5	75
115	Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5080-5087.	1.6	208
116	Symptomatic ocular metastases in lung cancer. <i>Respirology</i> , 2008, 13, 303-305.	2.3	25
117	Phase II randomized study of weekly docetaxel alone or plus UFUR treatment in non-small cell lung cancer patients who failed previous chemotherapy. <i>Lung Cancer</i> , 2008, 59, 64-68.	2.0	3
118	A phase II randomized study of vinorelbine alone or with cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly. <i>Lung Cancer</i> , 2008, 61, 214-219.	2.0	22
119	High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. <i>Lung Cancer</i> , 2008, 62, 78-84.	2.0	25
120	Survival Status of Veterans with Lung Cancer Is Poorer Than That Among Civilians Due to Age and Sex Differences: A Study of Chinese Veterans in Taiwan. <i>Journal of the Chinese Medical Association</i> , 2008, 71, 286-293.	1.4	2
121	Effect of Age on Pulmonary Metastases and Immunotherapy in Young and Middle-aged Mice. <i>Journal of the Chinese Medical Association</i> , 2007, 70, 94-102.	1.4	4
122	A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma. <i>Lung Cancer</i> , 2007, 56, 89-95.	2.0	11
123	A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan. <i>Lung Cancer</i> , 2007, 56, 363-369.	2.0	14
124	Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy. <i>Cancer</i> , 2007, 109, 1821-1828.	4.1	25
125	A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. <i>Lung Cancer</i> , 2006, 52, 333-338.	2.0	8
126	A Phase II Randomized Study of Paclitaxel Plus Carboplatin or Cisplatin against Chemo-Naive Inoperable Non-small Cell Lung Cancer in the Elderly. <i>Journal of Thoracic Oncology</i> , 2006, 1, 141-145.	1.1	11



#	ARTICLE	IF	CITATIONS
127	A Randomized Trial of Different Docetaxel Schedules in Non-small Cell Lung Cancer Patients Who Failed Previous Platinum-Based Chemotherapy. <i>Chest</i> , 2006, 129, 1031-1038.	0.8	81
128	Salvage Therapy for Chinese Non-small Cell Lung Cancer Patients Who Failed Previous Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2006, 1, 545-550.	1.1	5
129	A Phase II Randomized Study of Paclitaxel Plus Carboplatin or Cisplatin against Chemo-Naive Inoperable Non-small Cell Lung Cancer in the Elderly. <i>Journal of Thoracic Oncology</i> , 2006, 1, 141-145.	1.1	21
130	Salvage Therapy for Chinese Non-small Cell Lung Cancer Patients Who Failed Previous Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2006, 1, 545-550.	1.1	6
131	A Phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly. <i>Journal of Thoracic Oncology</i> , 2006, 1, 141-5.	1.1	8
132	Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy. <i>Journal of Thoracic Oncology</i> , 2006, 1, 545-50.	1.1	7
133	Chemotherapy for Non-small Cell Lung Cancer in Elderly Patients. <i>Chest</i> , 2005, 128, 132-139.	0.8	13
134	Gefitinib Treatment Is Highly Effective in Non-Small-Cell Lung Cancer Patients Failing Previous Chemotherapy in Taiwan: A Prospective Phase II Study. <i>Journal of Chemotherapy</i> , 2005, 17, 679-684.	1.5	19
135	Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 3750-3757.	7.0	295
136	Clinical Experience with Single-Agent Gemcitabine Chemotherapy in Patients with Non-Small-Cell Lung Cancer in Whom Previous Chemotherapy Has Failed. <i>Journal of the Chinese Medical Association</i> , 2005, 68, 163-166.	1.4	7
137	Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. <i>Lung Cancer</i> , 2005, 47, 129-138.	2.0	132
138	A randomized phase II study of vinorelbine plus gemcitabine with/without cisplatin against inoperable non-small-cell lung cancer previously untreated. <i>Lung Cancer</i> , 2005, 47, 373-380.	2.0	14
139	Impact of severe acute respiratory syndrome on the status of lung cancer chemotherapy patients and a correlation of the signs and symptoms. <i>Lung Cancer</i> , 2004, 45, 39-43.	2.0	32
140	Interleukin-2 stimulation activates mesothelial cellular functioning against autologous tumor cells. <i>Journal of the Chinese Medical Association</i> , 2004, 67, 323-30.	1.4	0
141	Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel. <i>Lung Cancer</i> , 2003, 39, 209-214.	2.0	20
142	Intrathecal gemcitabine chemotherapy for non-small cell lung cancer patients with meningeal carcinomatosis—a case report. <i>Lung Cancer</i> , 2003, 40, 99-101.	2.0	21
143	A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIb/IV) non-small-cell lung cancer patients aged 80 or older. <i>Lung Cancer</i> , 2003, 40, 221-226.	2.0	23
144	Paclitaxel plus gemcitabine may be as active and well tolerated as paclitaxel plus carboplatin for advanced non-small-cell lung cancer. <i>Cancer Treatment Reviews</i> , 2003, 29, 69-71.	7.7	1

#	ARTICLE	IF	CITATIONS
145	Phase II Study of Gemcitabine and Vinorelbine Combination Chemotherapy in Patients With Non-Small-Cell Lung Cancer Not Responding to Previous Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 567-570.	1.3	18
146	Phase II study with vinorelbine and cisplatin in advanced non-small cell lung cancer after failure of previous chemotherapy. <i>Journal of the Chinese Medical Association</i> , 2003, 66, 241-6.	1.4	7
147	Double Signal Stimulation was Required for Full Recovery of the Autologous Tumor-Killing Effect of Effusion-Associated Lymphocytes. <i>Chest</i> , 2002, 122, 1421-1427.	0.8	10
148	Phase II Study of Docetaxel and Gemcitabine Combination Chemotherapy in Non-Small-Cell Lung Cancer Patients Failing Previous Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 509-512.	1.3	29
149	An analysis of cytokine status in the serum and effusions of patients with tuberculous and lung cancer. <i>Lung Cancer</i> , 2001, 31, 25-30.	2.0	41
150	Interleukin-7 and Interleukin-12 Have Different Effects in Rescue of Depressed Cellular Immunity: Comparison of Malignant and Tuberculous Pleural Effusions. <i>Journal of Interferon and Cytokine Research</i> , 2001, 21, 249-256.	1.2	6
151	Usefulness of pig-tail catheter for palliative drainage of malignant pleural effusions in cancer patients. <i>Supportive Care in Cancer</i> , 2000, 8, 423-426.	2.2	22
152	Non-small Cell Lung Cancer in Very Young and Very Old Patients. <i>Chest</i> , 2000, 117, 354-357.	0.8	190
153	A Multicenter Phase II Trial of Vinorelbine Plus Gemcitabine in Previously Untreated Inoperable (Stage T <sub>1</sub> to T <sub>2</sub> ) Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 4314-4321.	0.8	41
154	A Phase II Study of Single-agent Docetaxel Chemotherapy for Non-small Cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2000, 30, 429-434.	1.3	17
155	Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy. <i>Lung Cancer</i> , 2000, 29, 139-146.	2.0	19
156	Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2000, 30, 199-202.	2.0	5
157	Restoration of the Immunocompetence by IL-2 Activation and TCR-CD3 Engagement of the In Vivo Anergized Tumor-Specific CTL from Lung Cancer Patients. <i>Journal of Immunotherapy</i> , 1997, 20, 354-364.	2.4	33
158	Cross Regulation by IL-10 and IL-2/IL-12 of the Helper T Cells and the Cytolytic Activity of Lymphocytes From Malignant Effusions of Lung Cancer Patients. <i>Chest</i> , 1997, 112, 960-966.	0.8	43
159	Elevation of Interleukin-10 Levels in Malignant Pleural Effusion. <i>Chest</i> , 1996, 110, 433-436.	0.8	50
160	Shortened Survival of Lung Cancer Patients Initially Presenting with Pulmonary Tuberculosis. <i>Japanese Journal of Clinical Oncology</i> , 1996, 26, 322-327.	1.3	32